|THP-0298||Human antihemophilic factor||Inquiry|
Hemophilia is a general term for a group of rare bleeding disorders caused by congenital deficiency of certain clotting factors. The most common form of hemophilia is classical hemophilia, also known as hemophilia A or factor VIII deficiency.
Hemophilia A is caused by disruption or mutation of the F8 gene. The F8 gene contains instructions that encode the anti-hemophilic factor VIII. Factor VIII is an essential blood protein that plays a role in helping the blood clot in response to injury. Mutations in the F8 gene cause the body to develop insufficient levels of functional factor VIII. The symptoms of hemophilia A occur as a result of this deficiency.
Hemophilia A is the most common X-linked recessive disorder and the second most common inherited coagulation factor deficiency after vascular hemophilia. The prevalence of hemophilia A is four times higher than that of hemophilia B (caused by factor IX deficiency). Hemophilia A predominantly affects males and is rarer in females (females have two X chromosomes). Approximately 1 in 5,000 male births has hemophilia A.
The severity and symptoms of hemophilia A vary from person to person. Individuals with mild hemophilia A may continue for many years without prolonged bleeding events. Individuals with moderate hemophilia A are at risk for prolonged bleeding after surgery, dental procedures, or trauma. More than half of those diagnosed with hemophilia A have a severe type. Patients in this group may experience spontaneous bleeding from any organ system, including the kidneys, gastrointestinal tract, and brain (intracranial bleeding). If left untreated, these frequent spontaneous bleeding events can be life-threatening.
Endogenous coagulation factor VIII is critical to the coagulation process in the body because it is involved in the coagulation cascade reaction. Congenital loss or deficiency of factor VIII leads to a physiological impairment of the coagulation cascade reaction, which results in easy bruising and bleeding. Although there is no complete cure for hemophilia A, for the time being, existing approaches have shown some success. These include exogenous replacement of factor VIII and prevention of complications associated with the disease. Most people will use human antihemophilic factors to treat or prevent bleeding events in people with hemophilia A.
Human antihemophilic factor is a non-recombinant, lyophilized concentrate of factor VIII. It can be obtained by artificially producing it in the laboratory and does not contain components from human blood. This replacement therapy is essential for hemophilia A. Human antihemophilic factor contributes to the conversion of prothrombin to thrombin. Its administration produces a complex that triggers the normal coagulation cascade reaction that forms thrombi. Thus increased human antihemophilic factor in plasma temporarily alleviates bleeding events in patients with hemophilia A.
Human antihemophilic factor helps hemophilia A patients to clot by temporarily increasing the level of factor VIII in the blood. Creative BioMart places emphasis on the prevention and control of hemophilia A. We provide our customers in the field of hemophilia research with high quality and stable human antihemophilic factors to help them in their research related to the cure of hemophilia A, development of new therapies, etc.
If you are interested in our product offerings or have any questions, please feel free to contact us for the latest news. We look forward to collaborating with you in your research on the prevention and control of hemophilia A with human antihemophilic factors.
For more information on how our products could help advance your project, please contact us.
ENTER YOUR EMAIL HERE TO SUBSCRIBE.
Copyright © Creative BioMart. All Rights Reserved.